| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | — | Argus Research | Downgrades | Buy → Hold | |
| 11/08/2023 | 68.22% | Needham | $12 → $9 | Maintains | Buy |
| 11/07/2023 | 30.84% | Rosenblatt | $11 → $7 | Downgrades | Buy → Neutral |
| 08/11/2023 | 124.3% | Needham | → $12 | Reiterates | → Buy |
| 08/09/2023 | 105.61% | Rosenblatt | $12 → $11 | Maintains | Buy |
| 08/09/2023 | 124.3% | Needham | $15 → $12 | Maintains | Buy |
| 08/07/2023 | 180.37% | Needham | → $15 | Reiterates | Buy → Buy |
| 06/09/2023 | 124.3% | Rosenblatt | → $12 | Reiterates | Buy → Buy |
| 05/19/2023 | 180.37% | Needham | → $15 | Reiterates | Buy → Buy |
| 05/15/2023 | 199.07% | Argus Research | $30 → $16 | Maintains | Buy |
| 05/10/2023 | 180.37% | Needham | $21 → $15 | Maintains | Buy |
| 05/10/2023 | 124.3% | Rosenblatt | $16 → $12 | Maintains | Buy |
| 04/12/2023 | 199.07% | Rosenblatt | $23 → $16 | Maintains | Buy |
| 04/12/2023 | 142.99% | Northland Capital Markets | → $13 | Downgrades | Outperform → Market Perform |
| 04/12/2023 | 292.52% | Needham | $28 → $21 | Maintains | Buy |
| 02/22/2023 | 479.44% | Cowen & Co. | $34 → $31 | Maintains | Outperform |
| 02/22/2023 | 423.36% | Needham | → $28 | Reiterates | → Buy |
| 09/26/2022 | 385.98% | Loop Capital | $21 → $26 | Upgrades | Hold → Buy |
| 09/08/2022 | 442.06% | Rosenblatt | $30 → $29 | Maintains | Buy |
| 08/08/2022 | 348.6% | Goldman Sachs | $21 → $24 | Maintains | Neutral |
| 07/14/2022 | 423.36% | Needham | → $28 | Initiates Coverage On | → Buy |
| 07/11/2022 | 423.36% | Rosenblatt | $25 → $28 | Maintains | Buy |
| 04/12/2022 | 367.29% | Rosenblatt | → $25 | Initiates Coverage On | → Buy |
| 02/23/2022 | 292.52% | Loop Capital | → $21 | Initiates Coverage On | → Hold |
| 08/06/2021 | 311.21% | Goldman Sachs | $20 → $22 | Maintains | Neutral |
| 08/06/2021 | 442.06% | Cowen & Co. | → $29 | Upgrades | Market Perform → Outperform |
| 05/18/2021 | 273.83% | Goldman Sachs | → $20 | Downgrades | Buy → Neutral |
| 05/14/2021 | 367.29% | Argus Research | → $25 | Upgrades | Hold → Buy |
| 02/05/2021 | 273.83% | Needham | → $20 | Upgrades | Hold → Buy |
| 11/04/2020 | 208.41% | Jefferies | → $16.5 | Upgrades | Hold → Buy |
| 04/17/2020 | 142.99% | Goldman Sachs | → $13 | Upgrades | Neutral → Buy |
| 10/10/2019 | — | MKM Partners | Downgrades | Buy → Neutral | |
| 01/29/2019 | — | Needham | Downgrades | Buy → Hold |
What is the target price for Adtran (ADTN)?
The latest price target for Adtran (NASDAQ: ADTN) was reported by Argus Research on November 20, 2023. The analyst firm set a price target for $0.00 expecting ADTN to fall to within 12 months (a possible -100.00% downside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adtran (ADTN)?
The latest analyst rating for Adtran (NASDAQ: ADTN) was provided by Argus Research, and Adtran downgraded their hold rating.
When is the next analyst rating going to be posted or updated for Adtran (ADTN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adtran, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adtran was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Adtran (ADTN) correct?
While ratings are subjective and will change, the latest Adtran (ADTN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Adtran (ADTN) is trading at is $5.35, which is out of the analyst's predicted range.